NEW YORK – Leica Biosystems and Sectra announced on Monday a collaboration to develop an integrated clinical pathology solution with an eventual intended submission to the US Food and Drug Administration for 510(k) clearance.
The collaboration will pair Sectra's digital pathology software solution with Leica Bio's Aperio AT2 DX system, a high-throughput automated digital scanner for diagnostic quality whole-slide images, which received 510(k) clearance earlier this year. The goal of the deal, the partners said in a statement, is to "address the needs of enterprise level customers such as academic medical centers, clinical research organizations, and large hospital networks." Integrating the two platforms, they added, will allow organizations to deliver a scalable, unified solution for better patient care and cost benefits.
Based in Linköping, Sweden, Sectra provides imaging IT solutions to the healthcare sector.
Financial and other terms of the deal were not disclosed.